Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.

Higham EM, Shen CH, Wittrup KD, Chen J.

J Immunol. 2010 Jun 1;184(11):5954-8. doi: 10.4049/jimmunol.1000265. Epub 2010 Apr 28.

2.

Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.

Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J.

J Immunol. 2012 Aug 15;189(4):1708-16. doi: 10.4049/jimmunol.1201271. Epub 2012 Jul 13.

3.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

4.

Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.

Olurinde MO, Shen CH, Drake A, Bai A, Chen J.

Cell Mol Immunol. 2011 Sep;8(5):415-23. doi: 10.1038/cmi.2011.18. Epub 2011 Jun 13.

5.

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Bai A, Higham E, Eisen HN, Wittrup KD, Chen J.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi: 10.1073/pnas.0805599105. Epub 2008 Aug 22.

6.

Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.

J Immunol. 2009 Oct 15;183(8):4848-52. doi: 10.4049/jimmunol.0900848.

8.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

9.

Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.

Higham EM, Wittrup KD, Chen J.

J Immunol. 2010 Apr 1;184(7):3394-400. doi: 10.4049/jimmunol.0903111. Epub 2010 Mar 3.

10.

CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.

Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S, Théry C, Amigorena S, Combadière C.

Neoplasia. 2013 Jan;15(1):85-94.

11.

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG.

Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 2009 May 12.

12.

CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L.

Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, Tarbell KV.

J Leukoc Biol. 2014 Feb;95(2):325-36. doi: 10.1189/jlb.0113013. Epub 2013 Sep 30.

13.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

14.

Distinct in vivo CD8 and CD4 T cell responses against normal and malignant tissues.

Coe D, Addey C, White M, Harwood N, Dyson J, Chai JG.

Cancer Immunol Immunother. 2013 Jan;62(1):101-12. doi: 10.1007/s00262-012-1316-3. Epub 2012 Jul 18.

PMID:
22806093
15.

CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Bak SP, Barnkob MS, Wittrup KD, Chen J.

Cancer Immunol Res. 2013 Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20.

16.

Antigen-specific effector CD4 T lymphocytes school lamina propria dendritic cells to transfer innate tolerance.

Cascio JA, Haymaker CL, Divekar RD, Zaghouani S, Khairallah MT, Wan X, Rowland LM, Dhakal M, Chen W, Zaghouani H.

J Immunol. 2013 Jun 15;190(12):6004-14. doi: 10.4049/jimmunol.1203552. Epub 2013 May 17.

17.

Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.

Choi DH, Kim KS, Yang SH, Chung DH, Song B, Sprent J, Cho JH, Sung YC.

Cancer Res. 2011 Dec 15;71(24):7442-51. doi: 10.1158/0008-5472.CAN-11-1459. Epub 2011 Oct 25.

18.

Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.

Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):337-49.

PMID:
12440225
19.
20.

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, Chandler P, Munn DH, Mellor A, Fu N, He Y.

J Immunol. 2010 Nov 1;185(9):5082-92. doi: 10.4049/jimmunol.1001821. Epub 2010 Oct 6.

Supplemental Content

Support Center